Industry news

• Russia to participate in setting up of NMIZs

  15 April 2013 Business Standard

  The government is offering a host of incentives like exemption from capital gains tax and a liberalised labour and environment norms to promote these zones.

• Rusnano asset and Pfizer to develop and market new drugs

  11 April 2013 Marchmont Innovation News

  BIND Therapeutics, a biotech asset of Russia’s Rusnano, has inked an agreement with Pfizer, a global pharma major, on the joint development and sales of innovation drugs, including cancer ones, Rusnano  announced . 
   

• EBRD supports Russian pharmaceutical industry

  11 April 2013 EBRD

  A Russian-owned and managed pharmaceutical company, GEROPHARM-Bio, a subsidiary of OOO Geropharm, has obtained a five-year EBRD loan to finance part of the cost of expanding and modernising of its production plant at Obolensk in the Moscow region in order to help it comply with international standards.

• Drug-company data vaults to be opened

  09 April 2013 Daniel Cressey, Nature.com

  European agency will publish firms’ clinical-trial results. 

  International calls for the pharmaceutical industry to share the results of clinical trials have grown ever more intense amid revelations that high-profile companies have hidden crucial data on safety and efficacy. Now Europe is moving towards measures that would significantly increase disclosure of such data.

• Rusnano Fund stimulates demand for nano products

  08 April 2013 Venture News

  The Government of Kaluga Region and Rusnano’s Fund for Infrastructure and Educational Programs (FIEP) have launched a programme to stimulate demand for nanotech products in the region, the press service of the fund reports.
   

• Here Are 3 Things Big Pharma Must Do To Survive - Joseph Jimenez

  04 April 2013 Max Nisen, Business Insider

  After years of relative stability and high profits, things aren't looking particularly rosy for the pharmaceutical industry. Blockbuster drugs are losing patent protection, R&D efforts haven't paid off as hoped, and prices will come under pressure from the Affordable Care Act.

• New Far East medical center may expect equipment from Rusnano or Japanese

  02 April 2013 Marchmont Innovation News

  Rusnano, Russia’s nanotech giant, is ready to join as a co-investor whatever private-public partnership (PPP) may form to equip the new high tech medical center to soon open at Vladivostok-based Far East Federal University (FEFU), the first such center in the Primorsky region in Russia’s Far East

• The revenue of Rusnano nanotech centers in 2012 is 365M RUR

  01 April 2013 Venture-news

  According to Rusnano, the revenue of Russian nanotech centers that were launched in 2012 under the auspices of the Fund for infrastructure and educational programs of Rusnano, JSC totaled 365M RUR. 

• Russian investment vehicle sets sights on innovative drugs

  29 March 2013 Eugene Gerden, Chemistry World

  

  Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. Rusnano has been ploughing hundreds of millions of dollars into pioneering pharma companies with the aim of growing Russia’s domestic drug production, and making a tidy return by licensing drugs to foreign partners.

• U.S. struggles with pharmaceutical goals in Asia trade talks

  29 March 2013 Doug Palmer, Reuters

  The United States is striving to find an appropriate balance in Asia-Pacific free trade talks between providing strong patent and data protections for U.S. drug manufacturers and ensuring poor people have access to medicine, a U.S. trade negotiator said on Thursday.